Aapro M - Search Results

1

Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.

Aapro M, Hesketh PJ, Jordan K, Gralla RJ, Rossi G, Rizzi G, Palmas M. Aapro M, et al. Oncologist. 2016 Apr;21(4):494-502. doi: 10.1634/theoncologist.2015-0301. Epub 2016 Mar 21. Oncologist. 2016. PMID: 27000465 Free PMC article.

2

Proposal for classifying the acute emetogenicity of cancer chemotherapy.

Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, Aapro MS, Gandara D, Lindley CM. Hesketh PJ, et al. Among authors: aapro ms. J Clin Oncol. 1997 Jan;15(1):103-9. doi: 10.1200/JCO.1997.15.1.103. J Clin Oncol. 1997. PMID: 8996130 Review.

3

Neoadjuvant therapy in breast cancer: can we define its role?

Aapro MS. Aapro MS. Oncologist. 2001;6 Suppl 3:36-9. doi: 10.1634/theoncologist.6-suppl_3-36. Oncologist. 2001. PMID: 11346684 Free article. Review.

4

Adjuvant therapy of primary breast cancer: a review of key findings from the 7th international conference, St. Gallen, February 2001.

Aapro MS. Aapro MS. Oncologist. 2001;6(4):376-85. doi: 10.1634/theoncologist.6-4-376. Oncologist. 2001. PMID: 11524557 Free article. Review.

5

Antiemetic guidelines: creating a more practical treatment approach.

Koeller JM, Aapro MS, Gralla RJ, Grunberg SM, Hesketh PJ, Kris MG, Clark-Snow RA. Koeller JM, et al. Among authors: aapro ms. Support Care Cancer. 2002 Oct;10(7):519-22. doi: 10.1007/s00520-001-0335-y. Epub 2002 Feb 21. Support Care Cancer. 2002. PMID: 12324805

6

Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.

Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R, Carides AD, Evans JK, Horgan KJ. Hesketh PJ, et al. Among authors: aapro m. Eur J Cancer. 2003 May;39(8):1074-80. doi: 10.1016/s0959-8049(02)00674-3. Eur J Cancer. 2003. PMID: 12736106

7

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.

Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M. Gralla R, et al. Among authors: aapro m. Ann Oncol. 2003 Oct;14(10):1570-7. doi: 10.1093/annonc/mdg417. Ann Oncol. 2003. PMID: 14504060 Free article. Clinical Trial.

8

Granisetron: an update on its clinical use in the management of nausea and vomiting.

Aapro M. Aapro M. Oncologist. 2004;9(6):673-86. doi: 10.1634/theoncologist.9-6-673. Oncologist. 2004. PMID: 15561811 Free article. Review.

9

Never too old? Age should not be a barrier to enrollment in cancer clinical trials.

Aapro MS, Köhne CH, Cohen HJ, Extermann M. Aapro MS, et al. Oncologist. 2005 Mar;10(3):198-204. doi: 10.1634/theoncologist.10-3-198. Oncologist. 2005. PMID: 15793223 Free article. Review.

10

5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?

Aapro M, Blower P. Aapro M, et al. Cancer. 2005 Jul 1;104(1):1-18. doi: 10.1002/cncr.21141. Cancer. 2005. PMID: 15929119 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

545 results

Search Page